加载中...

MedXY AI/MedXY News/Tag: clinical trials

MedXY News

EnglishTag

clinical trials

83 all articles · 20 / page

Ask MedXY AI

clinical trial immunotherapy type 2 diabetes heart failure obesity clinical trials atrial fibrillation Cardiology biomarkers oncology cardiovascular risk public health Hypertension critical care Alzheimer's disease artificial intelligence breast cancer nutrition diabetes cardiovascular disease Pediatrics chronic kidney disease

Latest news

Tag

Long-Acting Injectable ART Superior to Oral Regimens in Patients with HIV Adherence Challenges: Insights from the LATITUDE Trial

Long-Acting Injectable ART Superior to Oral Regimens in Patients with HIV Adherence Challenges: Insights from the LATITUDE Trial

The LATITUDE trial reveals that monthly injectable cabotegravir-rilpivirine significantly reduces treatment failure compared to standard oral ART in individuals with HIV who struggle with daily medication adherence, potentially reshaping cl

Section: Infectious DiseasesFeb 23, 2026

Serplulimab Plus Chemotherapy Redefines First-Line Standards in Non-Squamous NSCLC: Results from the ASTRUM-002 Trial

Serplulimab Plus Chemotherapy Redefines First-Line Standards in Non-Squamous NSCLC: Results from the ASTRUM-002 Trial

The Phase 3 ASTRUM-002 trial demonstrates that adding serplulimab to chemotherapy significantly extends progression-free survival in non-squamous NSCLC, though the further addition of a bevacizumab biosimilar (HLX04) did not provide statist

Section: newsFeb 19, 2026

Standard Preventive Interventions for Vasovagal Reactions Fail to Show Benefit in Massive 1.4 Million Donor Trial

Standard Preventive Interventions for Vasovagal Reactions Fail to Show Benefit in Massive 1.4 Million Donor Trial

The STRIDES trial, the largest of its kind, demonstrates that isotonic drinks, extended rest, modified muscle tension, and psychosocial support do not significantly reduce vasovagal reactions in blood donors compared to existing UK standard

Section: Hematology-OncologyFeb 19, 2026

Integrating Patient-Reported Outcomes Significantly Enhances the Reliability of Toxicity Assessments in Cancer Trials

Integrating Patient-Reported Outcomes Significantly Enhances the Reliability of Toxicity Assessments in Cancer Trials

A multinational randomized trial demonstrates that providing oncologists with patient-reported outcome data significantly improves the inter-rater reliability of CTCAE ratings for symptomatic adverse events, addressing a long-standing gap i

Section: Hematology-OncologyFeb 19, 2026

Doravirine and Islatravir Combination Proves Non-Inferior to B/F/TAF: A New Era for Two-Drug HIV Maintenance

Doravirine and Islatravir Combination Proves Non-Inferior to B/F/TAF: A New Era for Two-Drug HIV Maintenance

Phase 3 trial results demonstrate that a daily fixed-dose combination of doravirine and islatravir effectively maintains virological suppression in adults with HIV-1, offering a comparable and safe alternative to standard integrase inhibito

Section: Infectious DiseasesFeb 16, 2026

Metopimazine Mesylate (NG101) for Gastroparesis: Evaluating the Gap Between Patient Global Impression and Symptom Severity Scores

Metopimazine Mesylate (NG101) for Gastroparesis: Evaluating the Gap Between Patient Global Impression and Symptom Severity Scores

A Phase 2 trial of NG101 for gastroparesis missed its primary endpoint for nausea severity on the DIGS-DD scale but demonstrated significant improvements in Patient Global Impression of Change (PGIC) and a favorable safety profile, particul

Section: GastroenterologyFeb 4, 2026

A Glimmer of Hope for the ‘Slow Stomach’: Exploring the New Frontier in Gastroparesis Treatment

A Glimmer of Hope for the ‘Slow Stomach’: Exploring the New Frontier in Gastroparesis Treatment

This article examines the Phase 2 trial of NG101 (metopimazine), a novel treatment for gastroparesis. While the primary endpoint was missed, significant improvements in patient-reported outcomes and a strong safety profile suggest a potenti

Section: GastroenterologyFeb 4, 2026

Beyond Total Area: The GAWAIN Index Bridges the Gap Between Retinal Structure and Functional Vision in Geographic Atrophy

Beyond Total Area: The GAWAIN Index Bridges the Gap Between Retinal Structure and Functional Vision in Geographic Atrophy

Researchers have developed and validated GAWAIN, a novel structural measure for geographic atrophy that weights macular regions by their functional importance. This index correlates significantly better with visual acuity than traditional a

Section: newsJan 31, 2026

Crenezumab Fails to Meet Primary Endpoints in Preclinical Autosomal-Dominant Alzheimer’s: Insights from the API ADAD Colombia Trial

Crenezumab Fails to Meet Primary Endpoints in Preclinical Autosomal-Dominant Alzheimer’s: Insights from the API ADAD Colombia Trial

A Phase 2 trial of crenezumab in cognitively unimpaired PSEN1 mutation carriers found no significant clinical benefit over 5-8 years, suggesting that robust amyloid plaque removal may be essential for disease modification in early-stage Alz

Section: NeurologyJan 29, 2026

Selective TYK2 Inhibition in Atopic Dermatitis: Efficacy and Safety of ICP-332 in a Phase 2 Randomized Clinical Trial

Selective TYK2 Inhibition in Atopic Dermatitis: Efficacy and Safety of ICP-332 in a Phase 2 Randomized Clinical Trial

This review synthesizes findings from a Phase 2 trial of ICP-332, a novel TYK2 inhibitor, demonstrating significant EASI score improvements and a manageable safety profile in moderate to severe atopic dermatitis.

Section: Clinical UpdatesJan 30, 2026

Closing the Gap: Why Patient Perspectives Predict Survival Better Than Clinician Ratings in Sclerotic cGVHD

Closing the Gap: Why Patient Perspectives Predict Survival Better Than Clinician Ratings in Sclerotic cGVHD

A multicenter study reveals significant discordance between clinician and patient assessments of skin cGVHD. While both correlate with survival, patient-reported outcomes are uniquely predictive of mortality in sclerotic disease, highlighti

Section: DermatologyJan 26, 2026

Scaling the Notes: Feasibility Study Confirms Singing for Lung Health as a Viable Maintenance Strategy Post-Pulmonary Rehabilitation

Scaling the Notes: Feasibility Study Confirms Singing for Lung Health as a Viable Maintenance Strategy Post-Pulmonary Rehabilitation

A multicentre feasibility trial demonstrates that Singing for Lung Health (SLH) is a viable follow-up to pulmonary rehabilitation, showing high retention rates and strong participant enthusiasm for a definitive randomized controlled trial.

Section: Internal MedicineJan 22, 2026

High-Dose Walking Booster Program: A Feasible Strategy to Overcome Rehabilitation Plateaus in Chronic Stroke

High-Dose Walking Booster Program: A Feasible Strategy to Overcome Rehabilitation Plateaus in Chronic Stroke

The Phase II HiWalk trial demonstrates that a 43-hour high-intensity walking booster program is safe and feasible for chronic stroke survivors, yielding significant walking speed improvements for individuals who have already completed their

Section: NeurologyJan 21, 2026

Adjuvant Carboplatin Integration Redefines Survival Standards in Early-Stage Triple-Negative Breast Cancer: Insights from the RJBC 1501 Phase III Trial

Adjuvant Carboplatin Integration Redefines Survival Standards in Early-Stage Triple-Negative Breast Cancer: Insights from the RJBC 1501 Phase III Trial

The RJBC 1501 Phase III trial demonstrates that adding carboplatin to adjuvant EC-T chemotherapy significantly improves disease-free, distant disease-free, and overall survival in early-stage TNBC patients, despite a manageable increase in

Section: Hematology-OncologyJan 20, 2026

GSK-3β Inhibition with Elraglusib Shows Selective Activity and Biomarker Potential in Salivary Gland and Pancreatic Cancers

GSK-3β Inhibition with Elraglusib Shows Selective Activity and Biomarker Potential in Salivary Gland and Pancreatic Cancers

Clinical trials evaluate elraglusib, a GSK-3β inhibitor, in salivary gland and pancreatic cancers. While results were mixed, findings highlight the importance of nuclear GSK-3β expression as a biomarker and the need for dose optimization to

Section: newsJan 20, 2026

Durable Survival and Enhanced Downstaging: Long-term Insights from the NEOpredict-Lung Trial on Preoperative PD-1 and LAG-3 Blockade

Durable Survival and Enhanced Downstaging: Long-term Insights from the NEOpredict-Lung Trial on Preoperative PD-1 and LAG-3 Blockade

Extended follow-up of the NEOpredict-Lung trial demonstrates that short-course preoperative nivolumab, with or without relatlimab, yields high 3-year survival rates and significant nodal downstaging in resectable NSCLC, positioning dual che

Section: newsJan 19, 2026

Iptacopan: A Comprehensive Clinical Review of the First-in-Class Oral Factor B Inhibitor for PNH and Complement-Mediated Nephropathies

Iptacopan: A Comprehensive Clinical Review of the First-in-Class Oral Factor B Inhibitor for PNH and Complement-Mediated Nephropathies

This review synthesizes clinical trial evidence for Iptacopan, focusing on its transformative role in treating PNH through proximal complement inhibition and its emerging efficacy in IgA nephropathy and C3 glomerulopathy.

Section: Clinical UpdatesJan 19, 2026

Frontiers in Cardiometabolic Medicine: From Oral GLP-1 Small Molecules to RNAi Therapeutics

Frontiers in Cardiometabolic Medicine: From Oral GLP-1 Small Molecules to RNAi Therapeutics

This review synthesizes recent breakthroughs in obesity, type 2 diabetes, and lipidology, focusing on oral orforglipron, zodasiran for HoFH, and adolescent metabolic risk factors.

Section: Clinical UpdatesJan 18, 2026

Beyond the Futility Threshold: Deferoxamine May Accelerate Recovery and Benefit Specific Subgroups in Intracerebral Hemorrhage

Beyond the Futility Threshold: Deferoxamine May Accelerate Recovery and Benefit Specific Subgroups in Intracerebral Hemorrhage

While the primary i-DEF trial results suggested futility for deferoxamine in unselected intracerebral hemorrhage patients, recent post hoc analyses reveal significant benefits in early neurological improvement, long-term recovery trajectori

Section: NeurologyJan 18, 2026

Taladegib Shows Potential to Improve Lung Function in Idiopathic Pulmonary Fibrosis: Results from the ENV-IPF-101 Phase 2a Trial

Taladegib Shows Potential to Improve Lung Function in Idiopathic Pulmonary Fibrosis: Results from the ENV-IPF-101 Phase 2a Trial

The Phase 2a ENV-IPF-101 trial demonstrates that taladegib, a Hedgehog pathway inhibitor, not only stabilizes but may improve forced vital capacity and reduce fibrotic burden in patients with idiopathic pulmonary fibrosis over 12 weeks.

Section: Internal MedicineJan 14, 2026

Prev 1 2 3 4 5 Next